GlassScriptPhysician profile
Abdul H Sofi
NPI 1205885613
$5,309.25
in general payments reported to CMS, 2019-2025
38 companies · $578 in 2025
The $578 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $869 · 2021: $1,163 · 2022: $1,068 · 2023: $573 · 2024: $440 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $971.03 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $486.42 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $360.82 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $353.30 | 2021-2025 | |
| Lilly USA, LLC | $309.21 | 2020-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $277.29 | 2021-2023 | Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $260.83 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Eisai INC. | $214.60 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.23 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $174.73 | 2019-2023 | Belsomra, Januvia |
| Novartis Pharmaceuticals Corporation | $168.13 | 2019-2024 | |
| Cardiovascular Systems INC. | $163.10 | 2021 | |
| Pfizer INC. | $158.30 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $150.00 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $116.41 | 2019-2023 | Livalo, Seglentis |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Sofi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.